作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有43家上市原料药公司，其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到36%；60岁以上的CFO占比为5%；50岁-60岁的CFO群体占比为33%；40岁及以下CFO群体占比为26%。其中，目前仍任 从CFO的学历分布看，拥有高中、大专、本科、硕士学历的CFO占比分别为2%、12%、65%、21%。其中，以高中学历出任CFO的仅1人，为海森药业的潘爱娟。 从薪酬分布看，A股原料药公司CFO年薪平均值为66.12万元。经统计，处于50万以下、50万-100万、100万以上各区间的人数占比分别为44%、44%、12%。 其中，年薪排行前三的CFO分别为国邦医药的龚裕达、浙江医药的李齐融、新华制药的侯宁，三人年薪分别为193.09万元、184.18 万元、156.7万元。 从薪酬变 ...

作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有43家上市原料药公司，其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到36%；60岁以上的CFO占比为5%；50岁-60岁的CFO群体占比为33%；40岁及以下CFO群体占比为26%。其中，目前仍任 从CFO的学历分布看，拥有高中、大专、本科、硕士学历的CFO占比分别为2%、12%、65%、21%。其中，以高中学历出任CFO的仅1人，为海森药业的潘爱娟。 从薪酬分布看，A股原料药公司CFO年薪平均值为66.12万元。经统计，处于50万以下、50万-100万、100万以上各区间的人数占比分别为44%、44%、12%。 其中，年薪排行前三的CFO分别为国邦医药的龚裕达、浙江医药的李齐融、新华制药的侯宁，三人年薪分别为193.09万元、184.18 万元、156.7万元。 从薪酬变 ...

从薪酬分布看，A股原料药公司CFO年薪平均值为66.12万元。经统计，处于50万以下、50万-100万、 100万以上各区间的人数占比分别为44%、44%、12%。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到36%；60岁以上的CFO占比 为5%；50岁-60岁的CFO群体占比为33%；40岁及以下CFO群体占比为26%。其中，目前仍任职的最年 轻的上市公司CFO年龄33岁，为新诺威的戴龙。 从CFO的学历分布看，拥有高中、大专、本科、硕士学历的CFO占比分别为2%、12%、65%、21%。其 中，以高中学历出任CFO的仅1人，为海森药业的潘爱娟。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有43家上市原料药公司，其 聘任总体情况如下（部分统计 ...

Group 1 - Haisen Pharmaceutical's stock rose by 3.71% with a turnover rate of 35.09% and a trading volume of 357 million yuan, showing a volatility of 10.24% [2] - Institutional investors net sold 13.33 million yuan, while brokerage seats collectively net bought 22.75 million yuan [2] - The stock was listed on the Shenzhen Stock Exchange due to its high turnover rate, with institutional proprietary seats net selling 13.33 million yuan [2] Group 2 - The top five brokerage seats accounted for a total transaction volume of 69.38 million yuan, with a buying amount of 39.40 million yuan and a selling amount of 29.98 million yuan, resulting in a net buying of 9.42 million yuan [2] - Among the brokerage seats, three institutional proprietary seats were involved, with a total buying amount of 2.88 million yuan and a selling amount of 16.21 million yuan, leading to a net sell of 13.33 million yuan [2] - The stock experienced a net inflow of 26.09 million yuan from main funds today, including a net inflow of 5.32 million yuan from large orders and 20.77 million yuan from major funds, with a total net inflow of 61.36 million yuan over the past five days [2]

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by the company's general manager, Mr. Ai Lin, who has reduced his holdings in the company by 1,472,113 shares, representing 0.9690% of the total share capital [1][2]. Group 1: Share Reduction Details - Mr. Ai Lin executed the share reduction through centralized bidding, with an average reduction price of 21.7325 CNY per share [1]. - The total number of shares reduced was 1,472,113, with a price range between 21.3500 CNY and 22.2000 CNY per share [1][2]. - Prior to the reduction, Mr. Ai Lin held 6,014,252 shares, which accounted for 3.9587% of the total share capital [2]. Group 2: Post-Reduction Holdings - After the reduction, Mr. Ai Lin's remaining shares total 4,542,139, which is 2.9897% of the total share capital [2]. - The shares reduced were from the unrestricted category, leaving Mr. Ai Lin with only restricted shares [2]. Group 3: Compliance and Commitments - The share reduction plan was in compliance with relevant laws and regulations, including the Securities Law of the People's Republic of China [2][3]. - Mr. Ai Lin has adhered to his commitments regarding share transfers, including a lock-up period and conditions for future reductions [3][4]. - The reduction will not affect the company's control structure or governance [5].

证券代码：001367 证券简称：海森药业 公告编号：2025-030 浙江海森药业股份有限公司 关于公司董事、高级管理人员减持计划实施完成的公告 本公司董事、总经理艾林先生保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 份（包含前述股份因资本公积金转增股本增加的股份）； 注 2：本次减持价格区间为 21.3500 元/股—22.2000 元/股。 （二）股东本次减持前后持股情况 | 股东 | | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | --- | --- | --- | | 名称 | 股份性质 | 股数 | 占总股本 | 股数 | 占总股本 | | | | （股） | 比例（%） | （股） | 比例（%） | | 艾林 | 合计持有股份 | 6,014,252 | 3.9587 | 4,542,139 | 2.9897 | | | 其中：无限售条件股份 | 1,472,113 | 0.9690 | 0 | 0 | | | 有限售条件股份 | 4, ...

Group 1: Industry Development Direction - The company will enhance R&D innovation and improve product quality and production processes to solidify its market position in the raw material drug sector [1] - There will be increased investment in the R&D, production, and sales of chemical drug formulations, gradually extending into the formulation industry chain [1] - This extension aims to better meet customer needs, increase product added value, and enhance market competitiveness for sustainable development [1] Group 2: Market Value Management - The company emphasizes market value management through a series of measures, focusing on core business development and enhancing operational efficiency to drive value growth [2] - Active communication with investors is maintained through performance briefings and interactive platforms to enhance information transparency [2] - A reasonable and sustainable profit distribution plan is in place to create a long-term, stable shareholder value return mechanism [2] Group 3: Product Development Focus - Currently, the company has 17 products under research, covering areas such as antiviral, antidepressant, and lipid-lowering treatments [2] - Key development directions for the year include improving existing product processes to reduce production costs and enhance market competitiveness [2] - Accelerating the transition of existing raw material products to formulations and ensuring smooth commercialization of research products are prioritized to create new business growth points and profit sources [2]

029 浙江海森药业股份有限公司 关于公司董事、高级管理人员减持股份的预披露公告 本公司董事、总经理艾林先生保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：001367 证券简称：海森药业 公告编号：2025- 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 持有浙江海森药业股份有限公司（以下简称"公司"）股份 6,014,252 股 （占公司总股本的 3.96%）的董事、总经理艾林计划自本公告披露之日起 15 个交易日后的 3 个月内（即 2025 年 6 月 24 日至 2025 年 9 月 23 日）以集中竞 价交易方式或者大宗交易方式减持公司股份 1,472,113 股（占公司总股本的 0.97%）。 公司近日收到董事、总经理艾林先生出具的《关于股份减持计划的告知 函》，根据《上市公司股东减持股份管理暂行办法》《上市公司董事和高级管 理人员所持本公司股份及其变动管理规则》《深圳证券交易所上市公司自律监 管指引第 18 号——股东及董事、高级管理人员减持股份》等相关规定，现将相 关情况公告如下： 一、减持主体的基本情况 截至 ...

Group 1 - The core point of the article is that Haisen Pharmaceutical (001367) announced that its director and general manager, Ai Lin, plans to reduce his holdings by up to 1.4721 million shares, accounting for 0.97% of the company's total share capital, within three months after the announcement [1] - Ai Lin currently holds 3.96% of the company's shares, and the reason for the reduction is personal financial needs [1] - The reduction price will not be lower than the company's initial public offering price [1]

Core Viewpoint - Zhejiang Haisen Pharmaceutical Co., Ltd. has approved the use of idle raised funds for cash management, allowing up to RMB 300 million to be invested in low-risk, high-liquidity financial products, ensuring that it does not affect the normal operation of fundraising projects [1][3]. Group 1: Cash Management Implementation - The company has opened dedicated settlement accounts for cash management of raised funds at various securities firms, ensuring compliance with regulations [2]. - The accounts will only be used for the settlement of idle raised funds and will not be used for other purposes [2]. Group 2: Risk Control Measures - The company will adhere to relevant laws and regulations, including the "Regulations on the Supervision of Raised Funds by Listed Companies," to manage cash effectively and disclose information timely [2]. - Measures will be taken to control investment risks, including reporting potential risks and returns to the board's audit committee [3]. Group 3: Impact on the Company - The cash management of idle raised funds will not change the purpose of the funds or harm the interests of the company and its shareholders, ensuring normal business operations [3]. - This strategy is expected to improve the efficiency of fund utilization and increase returns on cash assets for the company and its shareholders [3].